Abstract. The performance of 2 competitive enzyme-linked immunosorbent assays (C-ELISA) was compared with the reference C-ELISA
Several recent reports on the development and evaluation of enzyme-linked immunosorbent assays (ELISAs), in particular the monoclonal antibody (MAb)-based ELISAs, 6, 4, 14 have stated that the competitive (C) ELISA may have the most potential to replace the agar gel immunodiffusion (AGID) test for serodiagnosis of bluetongue (BT). 4, 5, 1, 18 In 1984 Anderson 6 described a blocking (B) ELISA in which the immobilized BT virus (V) antigen (Ag), prepared from infected tissue culture (TC), was reacted with a test serum and then From the Animal Diseases Research Institute, Agriculture Canada, PO Box 11300, Station H, Nepean, Ontario K2H 8P9, Canada (Afshar, Trotter), the Australian Animal Health Laboratories, PO Bags 24, Geelong, Victoria 3220, Australia (Eaton) , the International Atomic Energy Agency, Wagramerstrasse 5, PO Box 100, A-1400 Vienna, Austria (Wright, Jeggo) , the National Veterinary Services Laboratories, USDA-APHIS, PO Box 844, Ames, IA 50010, USA (Pearson) , and the Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Woking GU24 ONF, UK (Anderson) .
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with a group-specific murine MAb. Anti-BTV antibody (if present in the test serum), having reacted with the antigen, blocked the subsequent reaction with the MAb in the next step of the assay. In 1987, Afshar et a1. 4 developed a C-ELISA that differed from the B-ELISA only in that the MAb was added to the reaction immediately after the addition of the test serum. The C-ELISA was more sensitive and specific than the AGID, modified complement fixation, and plaque neutralization tests. 4, 5 Subsequently, Lunt et a1. 14 and House et a1. 12 described a B-ELISA and a C-ELISA, respectively, in which other group-specific MAbs to BTV were used. Reddington et a1. 18 confirmed the superiority of the C-ELISA for serodiagnosis of BTV infection of ruminants and reported that the C-ELISA has comparable sensitivity to serum neutralization (SN) and Western immunoblot and immune precipitation assays. Unlike the AGID, no cross-reactions between BTV antigen and sera containing antibodies to epizootic hemorrhagic disease virus (EHDV) of deer were reported in any of the B-or C-ELISAs. [3] [4] [5] [6] 12, 14, 18 Comparison of B-and C-ELISAs utilizing different MAbs for the detection of anti-BTV antibodies in "check" panels of sera demonstrated that both assays have the potential to replace the AGID as the standard test. The C-ELISA is increasingly being used for national and international monitoring of ruminants for BTV exposure.
Among the BTV core polypeptides, 2 major proteins (VP3 and VP7) predominate and comprise approximately 50% of the total structural proteins of the virus l3 The VP7 protein has been identified as the soluble group-specific antigen and supposedly reacts specifically with the MAbs used in the B-and C-ELISAs. 6, 13, 14, 18 Recent developments in recombinant DNA technology have made the expression of BTV gene products possible in a variety of cells. 10, 11, 20 In 1990, Martyn et al. 15 reported the use of VP7 expressed in yeast as a diagnostic group-reactive antigen in a B-ELI-SA for the detection of BTV antibody in sera collected from experimentally infected animals.
This report compares the yeast-expressed VP7 antigen 5 and the TC-derived BTV core antigen 4, 6 in the C-ELISA. 4, 5 It also describes the results of a C-ELI-SA using the 8A3B.6 MAb 8 on a large number of field and experimental serum samples.
Materials and methods
Antigens for C-ELISAs. The TC-derived antigen stock (B454) was prepared from baby hamster kidney (BHK-21) cells infected in serum-free medium with plaque-purified BTV serotype T-11 by a method described previously. 6 This BTV antigen had 3.47 mg total protein/ml and was diluted 1:2,000 and tested with the Pirbright Laboratory (PL) MAb (3-17-A3) 6 and the American Type Culture Collection (ATCC) MAb (8A3B.6) in separate C-ELISAs. The major core protein VP7 of BTV T-1 was produced using a yeast expression system.
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The yeast-derived VP7 antigen was used at 1:1,500 or 1:1,000 with the PL MAb in the C-ELISA.
BTV group-specific MAbs. Two group-specific MAbs dation of a B-and C-ELISA. [4] [5] [6] [7] A batch of the hybridoma cell culture fluid a obtained by and maintained at the Animal Diseases Research Institute (ADRI) was used at an optimal dilution of 1:500 (final) with TC-derived BTV antigen in C-ELISA I. The same MAb (3-17-A3) was reacted at an optimal dilution of 1:16 (final) with VP7-Ag in C-ELISA III. The second MAb, identified as 8A3B. 6, 8 has been used for development of a C-ELISA. 12 The hybridoma (CRL1875) producing the MAb 8A3B.6 was obtained from the ATCC b and cultured according to a method described previously, 16 and the cell culture fluid was diluted at 1:1,500 for use in the C-ELISA II.
Serum samples. Sera from sequential blood samples from 26 crossbred 6-24-mo-old calves and 4 adult sheep experimentally infected with different serotypes of BTV were used in this study. Single calves were inoculated with BTV South African (SA) serotypes T-1-T-16 and T-18-T-20 and with USA serotypes T-11, T-13, and T-17. Groups of 4 calves and 4 sheep were inoculated with USA BTV T-10. Sera from several blood samples from groups of 2 calves infected with EHDV T-3 c and T-4 c were also tested. Sera from sequential blood samples from 2 calves experimentally infected with EHDV T-1 and challenged with EHDV T-2 and from 3 calves inoculated with EHDV T-2 and challenged with EHDV T-l were also included in this study.
d Sera from 2 other calves, inoculated with suckling mouse brain (SMB) infected with EHDV T-2 and then challenged with EHDV T-l, were propagated in SMB and then tested. The details of these experimental infections and other serologic results have been described elsewhere. 4, 9, 21, 22 A total of 618 field sera from cattle and sheep were used to evaluate the performance of the C-ELISAs. These sera included 171 samples from dairy cattle collected from herds in Ontario and 114 sheep sera obtained from the Diagnostic Unit, Health of Animals Laboratory, Sackville, New Brunswick. No record of BT activity nor any serologic evidence of BTV infection has ever been reported in these Canadian provinces, and all the samples tested negative in BT and EHD AGID assays. Bluetongue AGID-positive bovine sera were received from the USA: 193 samples from the 1985 US National BT Survey e and 193 samples from sentinel herds in Florida.
f A panel of 42 sheep sera received in 1972 from Barbados g were also tested by the C-ELISAs. All the sera against the core proteins of BTV were used in this study. The were transported on ice and stored at -20 C until used. PL MAb (3-17-A3) 6 has been used extensively in the vali-C-ELISAs. The C-ELISAs were performed according to the method described previously. 5 In preliminary tests, optimal concentrations of reagents for C-ELISAs were determined by checkerboard titrations, and all the sera were tested by the 3 procedures outlined in Table 1 . Optimal dilutions of BTV TC-Ag and VP7-Ag were adsorbed onto wells in microtiter plates. The plates were washed and incubated with diluted test sera and optimally diluted MAb. Following another wash cycle, the bound MAb was detected by goat antimouse IgG (H&L chain) conjugated with horseradish peroxidase.
h The enzymatic degradation of hydrogen peroxide in the presence of ABTS (azinoethylbenzthiazolinesulfonic acid) was measured spectrophotometrically, i using a computer-assisted target timing protocol as described elsewhere. 23 In accordance with the established value reported for the reference C-ELISA I, 5 bovine and ovine serum samples that inhibited ≥50% of the MAb activity in the C-ELISAs were considered positive.
AGID tests. The procedure used for the AGID has been described previously.
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Results
The combined results of the 3 BTV C-ELISAs for sera from 26 calves experimentally infected with the various SA and USA BTV serotypes are shown in Fig.  1A . Based on the 50% inhibition threshold, BTV antibody was variably demonstrable by all 3 C-ELISAs in sera from calves collected 10, 20, and 40 days postinfection (DPI). For the sera from single calves inoc- ulated with the various types, C-ELISA I demonstrated the greatest sensitivity in the detection of antibody, followed by C-ELISA III then by C-ELISA II. With the exception of 1 calf (C. 12-81) inoculated with BTV USA T-13, C-ELISA I detected all AGID-positive reactors at 10 DPI (Table 2 ). For the 3 calves (C.4-85, C.444, C.445) inoculated with BTV USA T-10, all 3 ELISAs detected anti-BTV antibodies at 9 DPI when the AGID tests in all cases were negative ( Table 2 ). The combined results of the 3 ELISAs for the detection of anti-BTV antibodies in serum samples from 4 sheep experimentally infected with USA BTV T-10 are shown in Fig. 1 B. Generally, the C-ELISAs were more efficient than the AGID test in the detection of antibodies in the early stage of infection. Antibody was demonstrable 7 DPI in the sera from 3 of 4 sheep by the C-ELISA I and C-ELISA III, and in 1 of 4 sheep by C-ELISA II (Table 2) . Precipitating antibodies were not demonstrable in any of these sheep by the AGID test on sera collected 7 DPI. Seroconversion was evident in all 4 sheep by all the C-ELISAs and the AGID tests on sera collected 20 DPI and thereafter (75 and 167 DPI). With the exception of 1 serum sample from a calf (OC.94) collected 8 months after infection with EHDV T-3, which gave an inhibition value of 65% in C-ELISA III, no cross-reacting antibodies to BTV were demonstrable by any of the C-ELISAs for sera collected from calves after primary inoculation with either EHDV T-1 or T-2 ( Fig. 2A, 2B ), T-3 or T-4 (Table 3) , nor from the same calves that received TC-derived EHDV T-l or T-2 initially and were challenged later with the het- erologous virus 9 ( Fig. 2A, 2B ). Postchallenge serum samples from 2 calves inoculated and challenged with SMB-derived EHDV T-2 and T-l, respectively, gave high levels of inhibition (87-93%) in all the C-ELISAs (Fig. 2C) .
The comparative frequency distribution of inhibition values in the C-ELISAs for 171 cattle and 114 sheep sera collected from BT-free populations are shown in Fig. 1C and 1D , respectively. All of the cattle sera resulted in values of <50% inhibition in all the C-ELISAs with the exception of 1 serum tested by C-ELISA I and 7 sera tested by C-ELISA III. These false-positive samples had inhibition values ranging from 50% to 54% (Table 4) . With the exception of 1 sheep serum sample that gave inhibition values of 65% and 69% in the C-ELISA I and C-ELISA III, respectively (Table 4) , all the sheep sera had inhibition values <50%. In the C-ELISA II, all values for cattle and sheep sera were below 50% inhibition with a pronounced distribution at the lower end of the inhibition scale (Fig. 1C, 1D) . No precipitating antibodies to BTV and EHDV T-l and T-2 were demonstrable in any of these cattle and sheep sera.
A comparative performance of the C-ELISAs in the testing of 285 sera from BTV-free areas of Canada and 333 field sera from cattle and sheep collected from BT-endemic areas is shown in Table 5 . These field sera included 193 samples from several sentinel herds of cattle in Florida, 98 BT AGID reactive samples from cattle in the USA, and 42 sheep sera collected from Barbados. The level of agreement between the C-ELI-SA I and either C-ELISA II or C-ELISA III, based on a positive threshold of 50%, was comparable. Of the samples from BTV-endemic areas, 11 bovine and 2 ovine serum samples had discrepant values (Table 6) . Although there were fewer sheep than cattle sera, the only disparity observed was with respect to C-ELISA III and the AGID results. A greater discrepancy was observed between AGID and the C-ELISA results for the 98 cattle sera from the USA. The available serum neutralization (SN) test results for 96 of these BT AGID reactive samples (G. A. Gustafson, personal communication) revealed that only 14 sera had SN antibodies to BTV, and these 14 sera were correctly classified as positive by the reference C-ELISA I. Of the remaining 82 samples, 24 sera had SN antibodies to EHDV, and 56 had no detectable SN antibodies to USA BTV T-2, T-10, T-11, T-13, and T-17 or EHDV T-l and T-2. Table 4 . Results of bluetongue (BT) AGID and discrepant C-ELISAs for some cattle (C) and sheep (S) collected from BT-free regions in Canada. Table 5 . Comparison of the performance of C-ELISA II and C-ELISA III with that of a reference assay, C-ELISA I, in the detection of antibody to bluetongue virus in 462 cattle and 156 sheep field sera.
Relative to C-ELISA I, the C-ELISA II was less sensitive (95.2%) but equally as specific (100%) in detecting antibodies to BTV in field sera from cattle and sheep and was the only test that produced no false positives. Ten bovine and 1 ovine sera positive by the C-ELISA I were negative by the C-ELISA II and had inhibition values of <50%. The C-ELISA III, relative to C-ELISA I, was less specific (95.8%) for cattle but equally as specific (100%) for sheep sera. Five bovine and 2 ovine sera with positive inhibition values ranging from 50% to 52% in the C-ELISA I were negative by the C-ELISA III, with values of 20-41%, resulting in a relatively less sensitive test (96.9%). The levels of overall agreement between the C-ELISA II and C-ELI-SA III, and the reference C-ELISA I for the bovine sera were 97.8% and 96.5% and for the ovine sera were 99.3% and 98.7%, respectively (Table 5) .
Discussion
Recent reports on the application of ELISAs for the detection of group-specific antibodies to BTV have Table 6 . Results of bluetongue (BT) AGID and discrepant C-ELISAs for serum samples collected from cattle (C) and sheep (S) form BT-endemic areas of the USA and Barbados.
supported the use of ELISA techniques, in particular the C-ELISA, instead of the AGID test for serodiagnosis of BT. [2] [3] [4] [5] [6] 12, 14, 18 Since the development and field evaluation of the C-ELISA, 4 ,5 novel reagents including MAbs 12, 14, 18 and genetically engineered BTV antigen 10, 11, 15 have been developed and used independently by several laboratories. The C-ELISA, 4 ,5 a modification of the B-ELISA 6 using PL MAb and TC-Ag, has gained popularity as a reference assay for standardization of similar tests utilizing different reagents. 12, 18 In this study, we compared the performance of 2 C-ELISAs, one using MAb 8 produced by a hybridoma obtained from ATCC and the other in which BTV VP7-Ag expressed in a yeast system 15 was used, in our routine C-ELISA. 5 Our results confirm the usefulness of ATCC MAb (8A3B.6) in the C-ELISA II and the VP7-Ag in the C-ELISA III. On a limited number of serum samples, other MAbs (i.e., 8B1B.1 and 7D3A.2 produced by ATCC hybridomas CRL-1877 and CRL-1886, respectively) 8 were reported to be useful in C-ELISA. 12 MAb 8B1B.1 and 7D3A.2 were also reactive in our C-ELISAs for the detection of anti-BTV antibodies (data not shown).
As previously reported, l5 the VP7-Ag was useful in the C-ELISA III in which the PL MAb had to be used at a higher concentration (1:16 final) compared to that dilution (1:500 final) used in the C-ELISA I with the TC-Ag. In a preliminary study, the ATCC MAb (8A3B.6) was useful at 1:150 dilution (final) in a C-ELI-SA in which the VP7-Ag was used (unpublished data).
Results of this study indicate that the performance of the C-ELISA using either ATCC MAb (8A3B.6) or VP7-Ag are comparable to that of the extensively validated C-ELISA I, and all C-ELISAs were more sensitive and specific than the AGID test in detecting group-specific antibodies to BTV. The sensitivity of the C-ELISA II relative to that of the reference C-ELI-SA I in detecting antibodies to BTV during the early phase of infection was low ( Table 2 , Fig. 1A, 1B) . In 5 of 24 calves, BTV antibody was demonstrable at 10 DPI by C-ELISA I but not by C-ELISA II. Whether such a difference is due to the specificity of the ATCC MAb and/or its affinity in relationship to the BTV TC-Ag determinants remains to be investigated. However, the ATCC MAb resulted in lower background activity in the C-ELISA II compared with that found in the C-ELISAs I and III (Fig. 1C, 1D) .
As reported previously, [3] [4] [5] [6] 12, 14, 18 unlike the AGID, the three ELISAs are highly specific for detecting antibodies to BTV. Anti-EHDV antibodies in serum samples from calves receiving a single dose of EHDV T-l, T-2, T-3, or T-4 do not result in false-positive reactions in the BTV C-ELISAs. However, false reactions at a higher level (87-93% inhibition) were found in sera of 2 calves inoculated and challenged with SMBderived EHDVs (Fig. 2C) . Repeated inoculation of calves with SMB-adapted EHDV could induce antibodies against mouse proteins (e.g., IgG) and could react with the MAb in a C-ELISA to give a false inhibition value. False-positive reactions have been reported for B-ELISA using antisera raised in animals receiving multiple injections of mouse brain-adapted EHDVs.
14 specificity in the testing of both cattle and sheep sera. Because limited numbers of ovine samples were available for this study, further assessment of the diagnostic specificity of the C-ELISA II on a large number of sheep sera is necessary. The sensitivity of the C-ELISA II was lower than that of the C-ELISA I in detecting antibodies early after infection. In 2 of 4 sheep, BTV antibody was demonstrable at 7 DPI by C-ELISA I but not by C-ELISA II, which may be a reflection of the ATCC MAb's immunological specification and/or affinity for BTV TC-Ag determinants in the C-ELISA II 'The specificity and sensitivity of the C-ELISA III were lower than those for the reference C-ELISA I (Table 5 ). However, in the testing of bovine sera there were 5 fewer false-negative samples and 11 false-positive samples in the C-ELISA III compared with those found in the C-ELISA II. The inhibition values for most of these samples were only 50% or slightly higher.
Western immunoblotting 1, 9 of false-positive samples may be beneficial; preadsorption of these sera with normal mouse brain tissue suspension may reverse the positive status of the samples in the C-ELISAs.
14 We have observed similar false reactions by the C-ELISA I in postchallenge sera from 3 horses, which received mouse brain-derived EHDV T-1, T-2, or T1/T2. Preabsorption of these sera with SMB eliminated the C-ELISA reactions (data not shown).
Novel reagents, e.g., MAb and yeast-expressed VP7 antigen, can be successfully utilized in C-ELISAs for the detection of group-specific antibodies to BTV. To recognize other effective MAb-based ELISAs for serodiagnosis of BT, reference reagents, e.g., BTV antigen and group-reactive MAb and a "check" panel of sera, are necessary for assay standardization. The collaborative institutions represented rently working toward this goal When field sera from 171 bovine and 114 sheep collected from BT-free areas were tested in the 3 ELISAs, a few sera gave inhibition values of 50% and slightly higher. Because the highest value in the 8 samples tested by the C-ELISA III was 54%, a higher negative cut-off value (e.g., 60%) could be selected as a threshold for this assay. One sheep sample (S.320) that resulted in inhibition values of 65% and 69% in C-ELI-SA I and C-ELISA III, respectively (Table 4) , was negative by AGID and in the standard SN assay, using
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in this study are cur-The positive AGID results for C-ELISA negatives may have been associated with the presence of crossreacting antibodies to EHDV or other orbiviruses [3] [4] [5] [6] 12, 14, 18 Of a panel of 82 sera positive on AGID for BTV, 24 samples (29.2%) had significant SN titers against EHDVs (G. A. Gustafson, personal communication). Whether the remaining AGID positives had cross-reacting antibodies to other orbiviruses is unknown.
Relative to the reference C-ELISA I, the C-ELISA II (employing the ATCC MAb [8A3B-6]) had equal 
